LV11431A - Holecistokinina antagonisti psihisko traucejumu arstesanai - Google Patents

Holecistokinina antagonisti psihisko traucejumu arstesanai

Info

Publication number
LV11431A
LV11431A LV960032A LV960032A LV11431A LV 11431 A LV11431 A LV 11431A LV 960032 A LV960032 A LV 960032A LV 960032 A LV960032 A LV 960032A LV 11431 A LV11431 A LV 11431A
Authority
LV
Latvia
Prior art keywords
treatment
holecistokinin
antagonists
mental disorders
antianxiety
Prior art date
Application number
LV960032A
Other languages
English (en)
Other versions
LV11431B (en
Inventor
David Christopher Horwell
John Hughes
Geoff Neil Woodruff
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27012795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV11431(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of LV11431A publication Critical patent/LV11431A/lv
Publication of LV11431B publication Critical patent/LV11431B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
LVP-96-32A 1989-08-04 1996-02-05 Central cholecystokinin antagonists for treatment of psychiatric disorders LV11431B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38966589A 1989-08-04 1989-08-04
US42189689A 1989-10-16 1989-10-16

Publications (2)

Publication Number Publication Date
LV11431A true LV11431A (lv) 1996-08-20
LV11431B LV11431B (en) 1996-12-20

Family

ID=27012795

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-96-32A LV11431B (en) 1989-08-04 1996-02-05 Central cholecystokinin antagonists for treatment of psychiatric disorders

Country Status (9)

Country Link
US (1) US5550126A (lv)
EP (2) EP0411668B2 (lv)
JP (1) JPH0374328A (lv)
AT (1) ATE119040T1 (lv)
CY (1) CY1983A (lv)
DE (1) DE69017302T3 (lv)
DK (1) DK0411668T4 (lv)
HK (1) HK8197A (lv)
LV (1) LV11431B (lv)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE119040T1 (de) * 1989-08-04 1995-03-15 Merck Sharp & Dohme Zentrale cholecystokinin-antagonisten zur behandlung von psychiatrischen krankheiten.
US5324726A (en) * 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
US5399565A (en) * 1990-07-17 1995-03-21 Eli Lilly And Company Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
US5206238A (en) * 1990-11-13 1993-04-27 Merck & Co., Inc. Cholecystokinin antagonists
US5218114A (en) * 1991-04-10 1993-06-08 Merck & Co., Inc. Cholecystokinin antagonists
US5218115A (en) * 1991-04-10 1993-06-08 Merck & Co., Inc. Cholecystokinin antagonists
US5220018A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
US5220017A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
EP0518484A3 (en) * 1991-05-14 1993-03-17 Merck & Co. Inc. 1,4-benzodiazepines condesed with 5- and 6-membered heterocyclic rings to treat anxiety, pain, pupil constriction, withdrawal-syndrome or oncologic disorders
US5185331A (en) * 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
US5206237A (en) * 1991-05-14 1993-04-27 Merck & Co., Inc. Benzodiazepine analogs
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
AU1766592A (en) * 1991-06-03 1993-01-08 Merck Sharp & Dohme Limited Pharmaceutical formulations of a benzodiazepine
US5177071A (en) * 1991-06-17 1993-01-05 Merck & Co., Inc. 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder
US5153191A (en) * 1991-08-20 1992-10-06 Warner-Lambert Company Cholecystokinin antagonists useful for treating depression
WO1993012791A1 (en) * 1991-12-20 1993-07-08 Merck Sharp & Dohme Limited Central cholecystokinin antagonists having pharmaceutical activity
IT1263116B (it) * 1992-04-09 1996-07-30 Rotta Research Lab Derivati basici dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso farmaceutico
US5438193A (en) * 1992-04-22 1995-08-01 Copan Company Limited Absolute rotary encoder with slit patterns having bit-coded tracks ranging from higher to lower order
US5360802A (en) * 1992-05-11 1994-11-01 Merck Sharpe & Dohme Ltd. Benzodiazepine derivatives, compositions containing them and their use in therapy
US5378838A (en) * 1993-01-13 1995-01-03 Merck & Co., Inc. Benzodiazepine cholecystokinin antagonists
US5852010A (en) * 1996-04-03 1998-12-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU3591697A (en) * 1996-07-02 1998-01-21 Merck & Co., Inc. Method for the treatment of preterm labor
US5929071A (en) * 1996-07-02 1999-07-27 Merck & Co., Inc. Method for the treatment of preterm labor
WO1999008667A2 (en) * 1997-08-19 1999-02-25 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
EP1313426A2 (en) * 1998-12-24 2003-05-28 Bristol-Myers Squibb Pharma Company Succinoylamino benzodiazepines as inhibitors of a-beta protein production
US7160880B1 (en) 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
AU5588400A (en) 1999-05-26 2000-12-18 Du Pont Pharmaceuticals Company 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6960576B2 (en) * 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
CA2384544A1 (en) 1999-10-08 2001-04-19 Bristol-Myers Squibb Pharma Company Amino lactam sulfonamides as inhibitors of a.beta. protein production
WO2001060826A2 (en) 2000-02-17 2001-08-23 Bristol-Myers Squibb Pharma Company SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
MXPA02009729A (es) 2000-04-03 2003-03-27 Bristol Myers Squibb Pharma Co Lactamas ciclicas como inhibidores de la produccion de la proteina a-beta.
MXPA02009755A (es) 2000-04-03 2003-03-27 Bristol Myers Squibb Pharma Co Lactamas ciclicas como inhibidores de la produccion de proteina a-beta.
US20100009966A1 (en) * 2001-04-11 2010-01-14 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of abeta protein production
JP2004500419A (ja) * 2000-04-11 2004-01-08 デュポン　ファーマシューティカルズ　カンパニー Ａβタンパク質産生阻害剤としての置換ラクタム
US6878363B2 (en) * 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
BR0106717A (pt) * 2000-06-01 2002-04-16 Bristol Myers Squibb Pharma Co Compostos, composição farmacêutica e usos dos compostos de lactama inovadora
US20090062256A1 (en) * 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
US20030139396A1 (en) * 2002-01-22 2003-07-24 Karen Gibson Method of treatment
US6713470B2 (en) * 2002-01-22 2004-03-30 Ml Laboratories Plc Method of treatment
US20040167146A1 (en) * 2002-01-22 2004-08-26 Karen Jackson Method of treatment
US20040043990A1 (en) * 2002-04-09 2004-03-04 Karen Jackson Method of treatment
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
CN104059071B (zh) 2006-07-10 2016-06-22 Paion英国有限公司 短效苯并二氮杂*盐及其多晶型
JP2010526825A (ja) * 2007-05-10 2010-08-05 エーエムアール テクノロジー インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンゾ−１，４−ジアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
KR102254957B1 (ko) 2013-11-22 2021-05-25 씨엘 바이오사이언시즈 엘엘씨 골다공증 치료 및 예방을 위한 가스트린 길항제(ｅｇ ｙｆ476, 네타제피드)
JP6682522B2 (ja) 2014-06-20 2020-04-15 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ２−（（４ｓ）−６−（４−クロロフェニル）−１−メチル−４ｈ−ベンゾ［ｃ］イソオキサゾロ［４，５−ｅ］アゼピン−４−イル）アセトアミドの結晶形態

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ212436A (en) * 1984-06-25 1989-04-26 Rotta Research Lab D,l-glutamic and d,l-aspartic acid derivatives and pharmaceutical compositions
CA1332410C (en) * 1984-06-26 1994-10-11 Roger M. Freidinger Benzodiazepine analogs
US5004741A (en) * 1984-06-26 1991-04-02 Merck & Co., Inc. Methods of antagonizing CCK or gastrin with benzodiazepine analogs
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
IT1215169B (it) * 1985-12-17 1990-01-31 Rotta Research Lab Derivati alchil ossigenati degli acidi glutammico ed aspartico ad attivita antagonista su polipeptidi bioattivi e procedimento per la loro preparazione
IT1217123B (it) * 1987-02-05 1990-03-14 Rotta Research Lab Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
ATE119040T1 (de) * 1989-08-04 1995-03-15 Merck Sharp & Dohme Zentrale cholecystokinin-antagonisten zur behandlung von psychiatrischen krankheiten.
US5153191A (en) * 1991-08-20 1992-10-06 Warner-Lambert Company Cholecystokinin antagonists useful for treating depression

Also Published As

Publication number Publication date
EP0727215A2 (en) 1996-08-21
ATE119040T1 (de) 1995-03-15
EP0411668A2 (en) 1991-02-06
DE69017302D1 (de) 1995-04-06
CY1983A (en) 1997-09-05
EP0411668A3 (en) 1992-01-29
HK8197A (en) 1997-01-24
US5550126A (en) 1996-08-27
EP0727215A3 (en) 1996-11-06
EP0411668B1 (en) 1995-03-01
JPH0374328A (ja) 1991-03-28
DE69017302T3 (de) 1999-08-05
DK0411668T3 (da) 1995-03-27
DK0411668T4 (da) 1999-08-09
LV11431B (en) 1996-12-20
DE69017302T2 (de) 1995-09-28
EP0411668B2 (en) 1998-11-11

Similar Documents

Publication Publication Date Title
LV11431A (lv) Holecistokinina antagonisti psihisko traucejumu arstesanai
FR13C0062I2 (fr) Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques
ATE398618T1 (de) Pharmazeutische zusammensetzungen zur behandlung von zns und anderen krankheiten
ATE101517T1 (de) Pharmazeutische zusammensetzung, enthaltend loratadin, ibuprofen und pseudoephedrin.
ATE348829T1 (de) Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
MA21264A1 (fr) Composition permettant d'administrer un medicament sous forme de gellules, d'une poudre ou d'un liquide.
MX9200361A (es) Nuevo uso del antagonista de adenosina.
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
ES2147616T3 (es) Derivados de piperidina con actividad antagonista del paf.
ATE172116T1 (de) Pharmazeutische anthocyanoside enthaltende zusammensetzungen zur oralen anwendung
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
DK0636027T3 (da) Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
DK598288D0 (da) Vaeskeformig farmaceutisk sammensaetning til behandling af hoste og oemhed i halsen
DK0391185T3 (da) 1,8-Naphthyridiner
ATE141796T1 (de) 2',5'-oligoadenylat-derivate zur verwendung als heilmittel
NO990450L (no) Behandling av sinnslidelser
FR2621915B1 (fr) Produits chimiques intermediaires utilisables pour la preparation de certains agents anti-histaminiques h2 et leur procede de preparation
DK0523013T3 (da) Anvendelse af benzimidazolin-2-oxo-1-carboxylsyrederivater ved behandling af organiske mentale sygdomme
ATE106874T1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
IT1246705B (it) Procedimento per l'eliminazione delle polveri nei filtri
IT1212137B (it) Composizioni farmaceutiche per il trattamento di sindromi psico-organiche cerebrali.
EA200200656A1 (ru) НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
DE68910021D1 (de) Oxaminsäureverbindungen und pharmazeutische Zusammensetzungen zur Anwendung bei der Verbesserung geschädigter Hirnfunktionen.
AR013096A1 (es) Sal de adicion de acido maleico de 5-(2-etil-2-h-tetrazol-5-il)-1-metil- 1,2,3,6-tetrahidropiridina, composicion farmaceutica que la contiene, su usoen terapia y metodo de preparacion de la misma.